Zborowski Jacek, Kida Dorota, Karolewicz Bożena, Jurczyszyn Kamil, Konopka Tomasz
Department of Periodontology, Wroclaw Medical University, ul. Krakowska 26, 50-425 Wroclaw, Poland.
Department of Drug Form Technology, Wroclaw Medical University, Borowska 211 A, 50-556 Wroclaw, Poland.
J Clin Med. 2025 Jan 21;14(3):681. doi: 10.3390/jcm14030681.
The study aimed to compare the effectiveness of photodynamic therapy (PDT) and topical clobetasol therapy in treating oral lichen planus (OLP). To address the absence of commercially available drug carriers, innovative proprietary solutions were developed. These carriers were designed to enhance the therapies: one for the photosensitizer to reduce its contact time with the mucosa, and another for the steroid to prolong its contact duration. A randomized, single-blind clinical trial lasting three months was conducted on 29 patients with bilateral oral lichen planus using a full contralateral split-mouth design. The authors utilized proprietary carriers containing 5% methylene blue and 0.025%. Lesion size, as well as scores on the Thongprasom, Abisis, and VASs, were assessed during the study. Relatively low rates of complete remission of lichen were demonstrated immediately after treatment, 10.3% after PDT and 3.4% after clobetasol, but after 3 months, 79% after PDT, and 62% after CLO. After 3 months of treatment, a reduction of 79.88% for PDT and 56.3% for CLO in the area of the evaluated lesions was achieved. PDT emerges as an equally effective method for treating OLP in terms of clinical outcomes, with the added advantage of avoiding many complications associated with conventional therapy.
该研究旨在比较光动力疗法(PDT)和外用氯倍他索疗法治疗口腔扁平苔藓(OLP)的效果。为了解决市售药物载体的缺失问题,开发了创新的专利解决方案。这些载体旨在增强治疗效果:一种用于光敏剂,以减少其与黏膜的接触时间,另一种用于类固醇,以延长其接触持续时间。采用完全对侧分口设计,对29例双侧口腔扁平苔藓患者进行了为期三个月的随机单盲临床试验。作者使用了含有5%亚甲蓝和0.025%的专利载体。在研究期间评估病变大小以及Thongprasom、Abisis和视觉模拟量表(VAS)评分。治疗后立即显示相对较低的扁平苔藓完全缓解率,PDT后为10.3%,氯倍他索后为3.4%,但3个月后,PDT后为79%,氯倍他索后为62%。治疗3个月后,评估病变区域的PDT减少了79.88%,氯倍他索减少了56.3%。就临床结果而言,PDT成为治疗OLP的同样有效的方法,具有避免许多与传统疗法相关并发症的额外优势。